Replies to post #188045 on Biotech Values

[DewDiligence]

(RVNC)—Merz’s Xeomin non-inferior to Botox in glabellar lines:

http://finance.yahoo.com/news/merz-aesthetics-announces-primary-endpoint-140000879.html

Xeomin is very similar to Botox, so this result is hardly surprising.

[DewDiligence]

Class-action suit filed against RVNC with respect to the company’s non-statements regarding formulation issues with RT001 (the topical botulinum-toxin product):

http://www.sec.gov/Archives/edgar/data/1479290/000119312515167699/d918520d8k.htm

As previously posted, if the decision were up to me, I would would drop RT001 and focus entirely on RT002, the injected botulinum-toxin product that RVNC claims is superior to Botox.